1 **Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae**
2 **from Southeast Queensland, Australia**

3

4 Stewart AG^{1,2}, Price EP^{3,4}, Schabacker K^{3,4}, Birikmen M^{3,4}, Harris PNA^{2,5}, Choong K¹, Subedi S^{1,6}
5 and Sarovich DS^{3,4#}

6 ¹Department of Infectious Diseases, Sunshine Coast University Hospital, Birtinya, QLD,
7 Australia

8 ²Centre for Clinical Research, University of Queensland, Herston, QLD, Australia

9 ³GeneCology Research Centre, University of the Sunshine Coast, Sippy Downs, QLD, Australia

10 ⁴Sunshine Coast Health Institute, Birtinya, QLD, Australia

11 ⁵Pathology Queensland, Central Microbiology, Royal Brisbane and Women's Hospital,
12 Herston, QLD, Australia

13 ⁶Department of Microbiology, Pathology Queensland, Sunshine Coast University Hospital,
14 Birtinya, QLD Australia

15

16 Keywords: Antibiotic, antimicrobial, resistance, cephalosporin, ESBL, whole-genome
17 sequencing, real-time PCR, Enterobacteriaceae

18

19 Running title: Population genomics of 3GC-R Enterobacteriaceae

20

21 #Corresponding author

22 Derek S. Sarovich

23 dsarovich@usc.edu.au

24 +61754563748

25 University of the Sunshine Coast, Locked Bag 4, Maroochydore DC, QLD, 4558, Australia

26

27 **Synopsis**

28 Third-generation cephalosporin-resistant (3GC-R) Enterobacteriaceae represent a major
 29 threat to human health. Here, we captured 288 3GC-R Enterobacteriaceae clinical isolates
 30 from 264 patients presenting at a regional Australian hospital over a 14-month period.
 31 Alongside routine mass spectrometry speciation and antibiotic sensitivity testing, isolates
 32 were examined using rapid (~40 min) real-time PCR assays targeting the most common
 33 extended spectrum β -lactamases (ESBLs; CTX-M-1 and CTX-M-9 groups, plus TEM, SHV, and
 34 an internal 16S ribosomal DNA control). AmpC CMY β -lactamase prevalence was also
 35 examined. *Escherichia coli* (80.2%) and *Klebsiella pneumoniae* (17.0%) were dominant, with
 36 *Klebsiella oxytoca*, *Klebsiella aerogenes* and *Enterobacter cloacae* infrequently identified.
 37 Ceftriaxone and ceftioxin resistance were identified in 97.0% and 24.5% of *E. coli* and *K.*
 38 *pneumoniae* isolates, respectively. Consistent with global findings in Enterobacteriaceae,
 39 most (98.3%) isolates harbored at least one β -lactamase gene, with 144 (50%) encoding
 40 *bla*_{CTX-M-1} group, 92 (31.9%) *bla*_{CTX-M-9} group, 48 (16.7%) *bla*_{SHV}, 133 (46.2%) *bla*_{TEM}, and 34
 41 (11.8%) *bla*_{CMY}. A subset of isolates (*n*=98) were subjected to whole-genome sequencing
 42 (WGS) to identify the presence of cryptic resistance determinants, and to verify genotyping
 43 accuracy. WGS of β -lactamase negative or carbapenem-resistant isolates identified
 44 uncommon ESBLs and carbapenemases, including *bla*_{NDM} and *bla*_{IMP}, and confirmed all PCR-
 45 positive genotypes. We demonstrate that our PCR assays enable the rapid and cost-effective
 46 identification of ESBLs in the hospital setting, which has important infection control and
 47 therapeutic implications.

48 Introduction

49 Third-generation cephalosporin-resistant (3GC-R) Enterobacteriaceae represent a significant
 50 threat to human health due to their ability to rapidly transmit antimicrobial resistance (AMR)
 51 determinants within and among bacterial populations (1). Both infection and colonization
 52 with these globally-disseminated organisms are associated with poor clinical outcomes and
 53 death (2). 3GC-R Enterobacteriaceae prevalence rates vary considerably among hospitals
 54 and countries, with particularly high rates in India, Asia, and the Middle East (3). Australia
 55 has historically observed a relatively low frequency of 3GC-R Enterobacteriaceae. However,
 56 this pattern may be changing, with an extended spectrum β -lactamase (ESBL) phenotype
 57 detected in 13.3% of *E. coli* and 9.8% of *K. pneumoniae* in blood culture isolates in 2018 (4),
 58 up from 2013 rates of 7.6% and 6.3%, respectively. Moreover, ceftriaxone resistance was
 59 seen in 13.4% of *E. coli* and 9.4% of *K. pneumoniae*, with 86.3% and 82.6% containing CTX-M-
 60 type ESBL genes, respectively (4).

61
 62 AMR in 3GC-R Enterobacteriaceae is generally conferred by the presence of an ESBL or the
 63 over-expression of a chromosomal or plasmid-borne AmpC β -lactamase (5). CTX-M-type
 64 ESBLs are currently the most common AMR determinants found in 3GC-R
 65 Enterobacteriaceae isolated in Australian hospitals, with *bla*_{CTX-M-1} and *bla*_{CTX-M-9} groups
 66 collectively comprising 86.2% of identified CTX-M-type enzymes (4). Detection of ESBL
 67 subtypes is not standard clinical practice; instead, their presence is typically inferred from
 68 antimicrobial susceptibility patterns and phenotypic confirmatory tests, which are laborious,
 69 costly (~\$AUD25/isolate), and time-consuming (>24h) to perform (6). Use of molecular-
 70 based diagnostics for AMR determinant detection in the clinical setting would improve
 71 patient outcomes by enabling more rapid, directed, and personalized treatment strategies,
 72 thereby improving antibiotic stewardship measures and reducing AMR burden. Their utility

73 has already been demonstrated in a number of clinical settings, including for bloodstream
 74 infections, pneumonia, and infection control screening (7-9).
 75
 76 In the current study, we prospectively collected all 3GC-R Enterobacteriaceae identified over
 77 a 14-month period at the Sunshine Coast University Hospital, Queensland, Australia, a 450-
 78 bed, regional teaching and tertiary hospital. Using large-scale comparative genomics, we
 79 developed a novel quadriplex and two singleplex real-time PCR assays to rapidly detect the
 80 most commonly identified β -lactamase (including ESBL) genes in 3GC-R Enterobacteriaceae.
 81 In association with WGS, we used our diagnostic real-time assays to determine the
 82 molecular epidemiology of the β -lactamase genes in our isolate set, and compared their
 83 performance with both genotypic and phenotypic typing methods to validate assay
 84 accuracy, sensitivity and specificity. Finally, we examined the population structure of our
 85 3GC-R Enterobacteriaceae population to identify potential cases of nosocomial spread or
 86 outbreak clusters.

87

88 **Materials and Methods**

89

90 **Ethics.** This study was approved by The Prince Charles Hospital Human Resources Ethics
91 Committee (HREC/18/QPCH/110). A waiver of informed consent was granted due to the low
92 to negligible risk associated with this study.

93

94 **Isolate collection.** Clinical specimens from 264 adult and pediatric patients (including ICU
95 patients [$n=48$]) that were culture-positive for 3GC-R Enterobacteriaceae were collected
96 prospectively from July 2017 through September 2018 at the Sunshine Coast University
97 Hospital microbiology laboratory ($n=288$). Multiple isolates were collected from 23 patients,
98 either due to re-infection over the course of the study ($n=9$), multiple samples taken during
99 initial admission ($n=11$), or collected during the course of their hospital stay ($n=3$). Samples
100 were inoculated onto ChromID™ ESBL agar (bioMérieux) and ChromID™ Carba/OXA agar
101 (bioMérieux) and examined for colored colonies at 18-24 hours. An ESBL screening disc test
102 was performed on isolates growing on ESBL agar. Isolates were speciated using the VITEK® 2
103 MALDI-TOF MS with the GN ID card (bioMérieux, Murrarie, QLD, Australia). Isolate
104 information is detailed in Table S1.

105

106 **Susceptibility testing.** Antibiotic susceptibility testing and minimum inhibitory concentration
107 (MIC) values were determined using VITEK® 2 or Etest (bioMérieux) according to the
108 manufacturer's instructions. EUCAST criteria (v.10.0) were used for susceptibility and
109 resistance interpretation.

110

111 **Culture DNA preparation.** For PCR, crude DNA was extracted from all isolates using 5%
112 chelex-100 resin (Bio-Rad Laboratories, Gladesville, NSW, Australia). For a subset of samples

113 (n=50), a pinhead-sized amount of culture collected using a sterile 10 µL pipette tip was
114 placed directly into 4 µL of PCR mastermix to facilitate rapid turnaround time. For WGS, DNA
115 was extracted using the Quick-DNA miniprep kit (Zymo Research, Irvine, CA, USA).

116

117 **PCR development and β-lactamase detection.** A quadriplex real-time PCR assay was
118 developed to detect the two major CTX-M ESBL groups (*bla*_{CTX-M-1} and *bla*_{CTX-M-9}) and *bla*_{SHV}
119 (both ESBL and non-ESBL); a 16S rDNA probe-based assay (10) was included in this
120 quadriplex to verify DNA integrity. Additionally, two singleplex assays were designed to
121 amplify ESBL and non-ESBL *bla*_{TEM} and *bla*_{CMY} β-lactamase genes (Figure 1). To identify
122 conserved regions for PCR assay design, all publicly available genetic sequences for *bla*_{CTX-M-1},
123 *bla*_{CTX-M-9}, *bla*_{CMY}, *bla*_{SHV}, and *bla*_{TEM} were downloaded from the NCBI Nucleotide database (as
124 of March 2019) and aligned using Clustal Omega v1.2.2. Aligned sequences were visualized
125 in Geneious v11.0.4. Candidate primers and probes were identified in Primer Express v3.0
126 (Applied Biosystems, Foster City, California, USA) or Primer3 v0.4.0 (11) followed by primer
127 dimer and heterodimer assessment using NetPrimer
128 (<http://www.premierbiosoft.com/netprimer/>).

129

130 Black Hole Quencher probes were used to enable multiplexing in a single PCR well and
131 robust target identification. For the quadriplex assay, the following primers and probes (5' to
132 3'; Macrogen Inc., Geumcheon-gu, Seoul, Republic of Korea) were designed: CTX-1 (CTX1_F:
133 CGAMACGTTCCGTCTCGAC, CTX1_R: CTTTCATCCAYGTCACCAGCTG, CTX1_P1: FAM-
134 CGTGATACCACTTCACCTCGGG-BHQ1), CTX-9 (CTX9_F: CGTCSCGCTCATCGATACC, CTX9_R:
135 CAGCTGCTTTGCGTTTCACTC, CTX9_P1: HEX-CGCTTTCCAATGTGCAGTACC-BHQ1), and SHV
136 (SHV_F: CCARCGTCTGAGCGCC, SHV_R: TATCGGCGATAAACCAGCCC, SHV_P1: Cy5-
137 CAGCACGGAGCGGATCA-BHQ2). The previously described 16S assay (10) incorporated a
138 different fluorophore on the probe (Texas Red-CACGAGCTGACGACARCCATGCA-BHQ2) to

139 accommodate the quadruplex assay format. Two singleplex assays targeting TEM and CMY
140 were also designed: TEM (TEM_F: TGTGGYGCGGTATTATCCCGT, TEM_R:
141 TGCATAATTCTTCTACTGTCAWGCCA, TEM_P1: Cy5.5-CACCAGTCACAGAAAAGCATCT-BHQ2),
142 CMY (CMY_F: TGGCGTATTGGYGATATGTA, CMY_R: TTATGCACCCATGAGGCTTT, CMY_Pr:
143 FAM-TGGGAGATGCTGAACTGGCC-BHQ1). Coincidentally, the reverse primer sequence for
144 our CMY assay was identical to one designed previously (12).

145
146 The quadruplex PCR was carried out using 0.1 µM 16S probe and primers, 0.2 µM CTX-1 and
147 CTX-9 probes and primers, 0.3 µM SHV primers, and 0.4 µM SHV probe. For the TEM
148 singleplex, 0.2 µM TEM primers and probe were used, and for the CMY singleplex, 0.2 µM
149 primers and 0.4 probe were used. All reactions contained 1X Sso Advanced Universal Probes
150 Supermix (Bio-Rad), primers, probe/s, 1 µL DNA template, and molecular grade H₂O, to a 5
151 µL total volume. PCRs were performed on a CFX96 Touch Real-Time PCR Detection System
152 using white Hard Shell 96-well PCR plates and Microseal 'C' Adhesive seals (Bio-Rad) or 0.2
153 mL white 8-tube PCR strips and optical caps (Bio-Rad). For bacterial cultures, thermocycling
154 conditions comprised an initial 2 min denaturation at 95 °C, followed by 45 cycles of 95 °C
155 for 1 sec and 60 °C for 3 sec (total run time=39 min).

156
157 **LoD and LoQ determination.** Three previously characterized strains (13) that represent the
158 PCR assays developed in this study – MER85 (*K. pneumoniae*), MER110 (*E. coli*), and MER132
159 (*E. coli*) – were subject to total DNA extraction using the Gram-positive bacteria extraction
160 protocol of the Qiagen DNeasy kit (Qiagen, Chadstone Centre, VIC, Australia). DNA quantities
161 were measured on the Qubit 4 fluorimeter (Thermo Fisher Scientific, Seventeen Mile Rocks,
162 Qld, Australia) using the Qubit dsDNA BR kit, and normalized to 40 ng/µL in molecular grade
163 H₂O. LoD and LoQ values were determined across 1:10 serial dilutions (range: 40 ng to 0.4
164 fg) using MER85 (*bla*_{TEM} singleplex), MER110 (*bla*_{CMY} singleplex), and a 50:50 mix of MER85

165 (*bla*_{CTX-M-1} group, *bla*_{SHV}) and MER132 (*bla*_{CTX-M-9} group) for the quadriplex assay. For PCR
166 thermocycling, denaturation and annealing times were increased to 5 sec and 10 sec,
167 respectively, to ensure assay robustness under very low DNA input conditions. Genome
168 equivalents were calculated by assuming *E. coli* and *K. pneumoniae* genome sizes of 4.984
169 Mbp and 5.638 Mbp, respectively.

170
171 **Assay specificity.** The quadriplex and singleplex assay amplicons were first assessed for
172 specificity *in silico* using the microbial nucleotide discontinuous BLAST tool and the Complete
173 genomes database (<http://blast.ncbi.nlm.nih.gov/>; performed March 2019). Next, assay
174 specificity was examined by laboratory testing against a range of both pathogenic and non-
175 pathogenic microbial species found humans. This diversity panel comprised *Achromobacter*
176 spp. (*n*=4), *Bordetella bronchiseptica* (*n*=1), *Candida albicans* (*n*=1), *Cupriavidus* sp. (*n*=2),
177 *Enterobacter aerogenes* (*n*=1), *Enterobacter cloacae* (*n*=3), *Enterococcus faecalis* (*n*=1),
178 *Klebsiella pneumoniae* (*n*=2), *Klebsiella oxytoca* (*n*=1), *Lactobacillus* spp. (*n*=2), *Prevotella*
179 spp. (*n*=6), *Pseudomonas aeruginosa* (*n*=10), *Staphylococcus aureus* (*n*=4), *Staphylococcus*
180 *epidermidis* (*n*=1), *Stenotrophomonas maltophilia* (*n*=5), and *Veillonella* spp. (*n*=4).

181
182 **Whole-genome sequencing (WGS).** WGS was performed at the Australian Centre of
183 Ecogenomics (University of Queensland, St Lucia, QLD, Australia) on the NextSeq 500
184 (Illumina, San Diego, CA, USA) with Nextera DNA Flex libraries (Illumina).

185
186 **Genomic analysis.** All genomic data were lightly quality-filtered using Trimmomatic v0.39
187 (14) using parameters described elsewhere (15). WGS data were screened for multiple
188 species using Kraken 2 v2.0.8 (16). Single species were assembled using MGAP v1.1
189 (<https://github.com/dsarov/MGAP---Microbial-Genome-Assembler-Pipeline>), whereas WGS
190 data containing multiple species were assembled with metaSPAdes (17). To determine

191 plasmid copy number and identity, plasmids were assembled using the plasmid module of
 192 SPAdes(18) with plasmid homology determined using BLAST(19). Assemblies were binned
 193 with MaxBin v2.0 (20) and speciated with Kraken 2 v2.0.8 (16). Antibiotic resistance genes
 194 were identified using the Resistance Gene Identifier (21). Phylogenomic analysis was
 195 performed using SPANDx v3.2.1 (22). Samples identified as containing multiple strains
 196 according to the method described by Aziz and colleagues (23) were excluded from
 197 phylogenetic analysis ($n=7$); samples able to be split into single species using MaxBin were
 198 included in phylogenetic analysis ($n=4$). *E. coli* O157:H7 Sakai (NCBI Assembly ID: ASM886v2)
 199 (24) or *K. pneumoniae* HS11286 (NCBI Assembly ID: ASM24018v2) (25) were used as read
 200 mapping reference genomes for species-specific analyses. To achieve the highest possible
 201 resolution, error-corrected assemblies of strains with matching multilocus sequence types
 202 (STs) were used as reference genomes for transmission analyses. ST profiles were
 203 determined using SRST2 v0.2.0 (26). Phylogenetic trees were reconstructed using PAUP
 204 v4.4.7 (27) and visualized in iTOL v5.5(28).

205

206 **WGS data.** Raw sequence reads generated in this study are available on the NCBI Sequence
 207 Read Archive database under BioProject accession number PRJNA606985.

208 Results and Discussion

209 ESBL enzymes have established themselves as major contributors of AMR in Gram-negative
 210 bacteria and are increasing in prevalence, particularly in the community setting. Over 14
 211 months, we collected a total of 288 isolates from all diagnosed cases of 3GC-R
 212 Enterobacteriaceae in a regional hospital in Southeast Queensland, Australia. Our patient
 213 cohort was predominantly female (64.0%) and aged over 65 (60.9%). ICU patient specimens
 214 comprised 54 (18.8%) of the total collection, and were obtained from 48 ICU patients over a
 215 12-month period. Five ICU patients had multiple isolates collected over the course of their
 216 stay in the ICU. Three patients isolated single species with identical AMR profiles, two
 217 patients isolated multiple species: one with identical AMR profiles and one with differing
 218 profiles (Table S1). *E. coli* and *K. pneumoniae* were dominant, comprising 80.2% and 17.0%
 219 3GC-R strains, respectively (Table 1 and S1). The remaining isolates were identified as *E.*
 220 *cloacae* (1.4%; *n*=4), *K. oxytoca* (1.0%; *n*=3), and *K. aerogenes* (0.3%; *n*=1). Resistance to
 221 ceftriaxone, ceftazidime or cefepime was common and observed in 96.2%, 93.4%, and 86.8%
 222 of isolates, respectively. In contrast, ceftiofex resistance was noted in only 81 (28.1%)
 223 isolates (Table 1). Meropenem resistance was rare, with only six resistant strains (2.1%)
 224 identified. The double disc diffusion method for ESBL phenotypic testing was negative in 32
 225 (11.1%) isolates, indicating a lack of β -lactamase inhibition in the presence clavulanic acid.
 226 The remaining 256 (88.9%) isolates were positive for this phenotypic test.

227
 228 *ESBL and β -lactamase assay performance.* Preliminary validation of our singleplex (*bla*_{TEM},
 229 *bla*_{CMY}) and quadruplex (*bla*_{CTX-M-1} group, *bla*_{CTX-M-9} group, *bla*_{SHV}, 16S rDNA) PCR assays was
 230 performed to determine their accuracy and specificity. Following *in silico* verification, assays
 231 were tested on 12 previously characterized control strains (Table S2) (29) that represented a
 232 range of Enterobacteriaceae containing the gene targets of interest. All expected targets
 233 were identified in this control dataset; no false positives or false negatives were detected,

234 although both the *bla*_{TEM} and 16S rDNA assays yielded late (>30 cycles) amplification in no-
 235 template control wells (Figure 1). This result was expected due to residual *E. coli* DNA
 236 presence in the recombinant Sso Advanced *Taq* polymerase, which encodes both *bla*_{TEM} and
 237 16S rRNA genes.

238

239 We found that all genotypes could be accurately determined for the control strains by
 240 directly inoculating PCR wells with a very small amount of bacterial culture, thereby
 241 obviating the need for DNA extraction and leading to faster time-to-diagnosis. However, this
 242 technique requires skill to ensure that the PCR is not inhibited by excess DNA and cellular
 243 constituents, and can lead to greater PCR failures if not performed correctly. In addition, we
 244 recommend using 10 µL rather than 5 µL total PCR volume as, in our hands, the lower
 245 reaction volume led to a greater failure rate. Inclusion of the 16S rDNA assay enables true
 246 negatives to be differentiated from PCR failures. This method provides an attractive option
 247 where rapid diagnosis is paramount, or where DNA extraction is not feasible.

248

249 Next, we screened our PCR assays across a diversity panel of non-Enterobacteriaceae human
 250 pathogens or colonizers (*n*=48 strains). Our assays showed 100% sensitivity and specificity
 251 for all targets, with no amplification detected in these isolates, except for the 16S target in
 252 bacterial strains; as with the control dataset, the *bla*_{TEM} PCR was inhibited by the presence of
 253 non-*bla*_{TEM}-encoding DNA and therefore did not amplify in any diversity panel strains.

254

255 *LoQ and LoD determination of the ESBL and β-lactamase assays.* Using serial dilutions of
 256 previously characterized DNA samples ranging from 40 ng to 0.4 fg, the LoQ values for each
 257 assay were identified (Figure 2) as follows: *bla*_{CMY}, 400 fg (~73 genome equivalents [GEs]);
 258 *bla*_{TEM}, 400 fg (~65 GEs); 16S rDNA, 40 fg (~3 GEs); *bla*_{CTX-M-1} group, 4 pg (~344 GEs); *bla*_{CTX-M-9}
 259 group, 4 pg (~344 GEs); and *bla*_{SHV}, 4 pg (~344 GEs). LoD values for each assay were: *bla*_{CMY}, 4

260 fg (~7 GEs); *bla*_{CTX-M-1} group, 4 pg (~344 GEs); *bla*_{CTX-M-9} group, 400 fg (~34 GEs); and *bla*_{SHV},
 261 400 fg (~34 GEs). Due to low levels of recombinant *E. coli* DNA present in the Sso Advanced
 262 *Taq* polymerase, which results in late amplification in no-template control wells, LoD values
 263 for the *bla*_{TEM} and 16S rDNA assays could not be determined. As expected, these results
 264 indicate inferior performance of the quadriplex assay when compared with the singleplex
 265 assays. Although not examined in this study, increased LoQ and LoD values may be achieved
 266 for the *bla*_{CTX-M-1} group, *bla*_{CTX-M-9} group, and *bla*_{SHV} assays by omitting the 16 rDNA assay, or
 267 by running these assays in singleplex format. Although we have defined the limits of our
 268 assays using pure bacterial templates, it remains to be determined what detection limits
 269 would be achieved from clinical specimens.

270
 271 *ESBL and β-lactamase prevalence in clinical 3GC-R Enterobacteriaceae isolates.* Following
 272 specificity confirmation, the PCR assays were tested across our clinical set (*n*=288). All assays
 273 performed well, with 100% concordance between PCR genotypes and WGS of 98 isolates,
 274 and with no false negatives identified (Table S3). Overall, a β-lactamase genotype was
 275 identified in 277 (96.2%) isolates. Consistent with previously reported rates (29), *bla*_{CTX-M-1}
 276 group was most common, being identified in 144/288 (50%) isolates, including 105/231
 277 (45.5%) *E. coli* and 36/49 (73.5%) *K. pneumoniae*. The *bla*_{CTX-M-9} group was next frequent,
 278 being found in 93/288 (32.3%) isolates, including 89/231 (38.5%) *E. coli* and 4/49 (8.2%) *K.*
 279 *pneumoniae*. The presence of both *bla*_{CTX-M-1} group and *bla*_{CTX-M-9} group enzymes was
 280 identified in five (1.7%) *E. coli* and one (2.0%) *K. pneumoniae* isolate. Of the eight isolates
 281 belonging to other species, *bla*_{CTX-M-1} and *bla*_{CTX-M-9} group genes were present in 4/8 (50%)
 282 and 0/8 (0%) of these isolates, respectively. The acquired *ampC* gene, *bla*_{CMY}, was identified
 283 in 30/231 (13%) of *E. coli*, 3/49 (6.1%) of *K. pneumoniae*, and 1/8 (13%) other
 284 Enterobacteriaceae species. *bla*_{CMY} and *bla*_{CTX-M-1} were both identified in seven isolates (five

285 *E. coli*, one *K. pneumoniae*, and one *E. cloacae*) and *bla*_{CMY} and *bla*_{CTX-M-9} were present in two
286 *E. coli* isolates only (Table 1).

287

288 Seven strains (five *E. coli* and two *K. pneumoniae*) had *bla*_{SHV} only; nine *E. coli* had *bla*_{TEM}
289 only, and seven (five *K. pneumoniae*, one *E. coli*, and one *E. cloacae*) had both *bla*_{SHV} and
290 *bla*_{TEM}. Although most SHV (e.g. *bla*_{SHV-1}) and TEM (e.g. *bla*_{TEM-1}, *bla*_{TEM-2}) enzymes do not
291 typically cause 3GC-R, their presence in strains that lack CTX-M-type ESBLs should be
292 investigated, as these enzymes can occasionally confer 3GC-R through enzyme active site
293 mutation or gene overexpression (5). Of the 14 strains encoding *bla*_{SHV} but not *bla*_{CTX-M-1}
294 group, *bla*_{CTX-M-9} group, or *bla*_{CMY} enzymes, five had accompanying WGS data, which
295 permitted assessment of *bla*_{SHV} ESBL status. In all cases, the *bla*_{SHV} variant was an ESBL (two
296 *bla*_{SHV-2}, one *bla*_{SHV-64}, one *bla*_{SHV-66}, and one *bla*_{SHV-134}) (30). In contrast, none of the four
297 strains encoding *bla*_{TEM} but not *bla*_{CTX-M-1} group, *bla*_{CTX-M-9} group, *bla*_{CMY}, or ESBL-encoding
298 *bla*_{SHV} enzymes were ESBLs, with all being *bla*_{TEM-1}. Three of these were negative with the
299 double disc diffusion method, indicating probable chromosomal mutations underpinning this
300 phenotype. The basis for the ESBL phenotype in the fourth strain could not be elucidated.

301

302

303 *Correlation between bla*_{CMY} *and ceftazidime resistance*. Of the 81 ceftazidime-resistant isolates,
304 *bla*_{CMY} was detected in only 31 (38.3%) cases. Although imperfect, ceftazidime resistance is
305 often used as a marker for AmpC presence (32). Correlation is also dependent on the MIC,
306 with higher MICs more reliably predicting AmpC presence (32). Our findings concur with this
307 prior work, with 61.7% of ceftazidime-resistant isolates failing to amplify *bla*_{CMY}. AmpC has
308 previously been reported as an underappreciated mechanism of 3GC-R due to a lack of
309 standardized testing (33). As such, molecular methods that can detect other common and
310 emerging β -lactamase gene families (e.g. *bla*_{DHA}, *bla*_{OXY}, *bla*_{MIR}) may prove useful for infection

311 control management and treatment of multidrug-resistant infections. This is particularly true
312 for piperacillin-tazobactam, which may not be effective against AmpC producers (29, 34).

313

314 *WGS identifies uncommon ESBL genes.* Eleven (3.8%) PCR-negative isolates that otherwise
315 successfully amplified their 16S rDNA internal control (seven *E. coli*, one *K. pneumoniae*, one
316 *K. oxytoca*, one *K. aerogenes* and one *E. cloacae*) were subjected to WGS to determine the
317 molecular basis of 3GC-R. Six were found to carry uncommon β -lactamase enzymes, with
318 three *E. coli* encoding *bla*_{DHA-1}, one *K. pneumoniae*/*K. oxytoca* mixture harboring *bla*_{OXY-2-4},
319 one *K. oxytoca* carrying *bla*_{OXY-2-1}, and one *E. cloacae* carrying *bla*_{ACT-17}. The remaining five
320 isolates had no discernable 3GC-R determinants, although misclassification via automated
321 susceptibility testing or upregulation of chromosomal β -lactamases are both possible causes
322 for this discrepancy.

323

324 Six isolates (three *E. cloacae*, two *E. coli* and one *K. pneumoniae*) exhibiting meropenem
325 resistance alongside 3GC-R were also subjected to WGS to determine the basis of resistance
326 towards this carbapenem. As expected, meropenem resistance was mostly conferred by
327 carbapenemases, with 4/6 (66.6%) isolates possessing one of these enzymes. *bla*_{NDM-1} or
328 *bla*_{IMP-4} were identified in two *E. cloacae* isolates, *bla*_{NDM-5} was identified in an *E. coli* strain,
329 and an OXA-48-like enzyme, *bla*_{OXA-232} was identified in a *K. pneumoniae* isolate. No
330 carbapenemase gene could be identified in the remaining two isolates (one *E. coli* and one *E.*
331 *cloacae*). Although not investigated in this study, chromosomally-encoded porin loss or
332 efflux pump overexpression may form the basis of meropenem resistance in these strains.

333

334 *Monitoring patient-to-patient spread in an ICU.* Fifty-four (18.8%) 3GC-R isolates obtained
335 during this study originated from ICU-admitted patients. Due to their dominance, only *E. coli*
336 and *K. pneumoniae* genomes were analyzed for potential transmission events. Among the *E.*

337 *coli* population (Figure 3), isolates SCHI0016.S.60 and SCHI0016.S.62, and SCHI0016.S.265
338 and SCHI0016.S.46, were separated by 10 SNPs and 2 SNPs, respectively; however, both
339 pairs came from individual patients, reflecting expected levels of within-host evolution of a
340 single infecting strain. *E. coli* isolates SCHI0016.S.42 and SCHI0016.S.294 were very similar,
341 being separated by 13 SNPs. Although both strains were isolated from ICU-admitted
342 patients, SCHI0016.S.294 was isolated 306 days after SCHI0016.S.42 with no other linking
343 epidemiology identified. Additionally, no similar strains were isolated from ICU patients over
344 this time period suggesting that these do not represent transmission. *E. coli* isolates
345 SCHI0016.S.172 and SCHI0016.S.274 differed by ~300 SNPs, with no epidemiological or
346 temporal correlation. ~300 SNPs separated SCHI0016.S.112 and SCHI0016.S.229, again with
347 no demonstrable epidemiological link. Among *K. pneumoniae* (Figure 4), the closest isolates,
348 SCHI0016.S.15 and SCHI0016.S.261, differed by 361 SNPs, with no epidemiological link.
349 Additionally, no horizontal transfer of plasmids carrying ESBL determinants was observed. As
350 standard practice, all ICU patients, and all patients in other wards infected or colonized with
351 ESBL-producing *E. coli* and *K. pneumoniae*, have single rooms with an assigned nurse (1:1
352 ratio), with contact precautions exercised. In addition, hand hygiene rates in our hospital ICU
353 are generally above 80% (35). Taken together, our results demonstrate no evidence of
354 transmission in the ICU, suggesting that the implemented hygiene measures are effective.
355
356 *Population structure of E. coli and K. pneumoniae genomes.* We subjected an additional 36
357 strains to WGS (total $n=98$) to capture a snapshot of genomic diversity and population
358 structure (Figures 3 and 4). *In silico* MLST of the 79 *E. coli* strains found that ST131 was most
359 common ($n=11$; 13.9%). This finding is consistent with a recent study of the population
360 structure of Australian, New Zealand, and Singaporean multidrug-resistant *E. coli* isolates
361 (29). The highly successful ST131 clone has now spread worldwide, where it frequently
362 causes urinary tract and bloodstream infections and accounts for 12–27% of all community-

363 acquired *E. coli* infections (36, 37). Among our ST131 isolates, we found high frequencies of
 364 fluoroquinolone resistance-conferring variants (GyrA_{S83L}, GyrA_{D87N}, ParC_{S80I} and ParC_{E84V})
 365 alongside frequent carriage of plasmid-borne CTX-M-14 (CTX-M-9 group) and CTX-M-15
 366 (CTX-M-1 group) ESBLs. We also identified three strains belonging to the emerging multi-
 367 drug resistant pandemic clone, ST1193. These isolates also possessed the same three
 368 fluoroquinolone-resistant SNPs as ST131. It has been proposed that ST1193 strains evolved
 369 fluoroquinolone resistance relatively recently through multiple recombination events with
 370 other *E. coli* strains (38).

371
 372 Phylogenomic analysis of our 10 *K. pneumoniae* genomes identified several distinct lineages,
 373 which comprised two ST14 strains and one each of ST17, ST307, ST309, ST395, ST656, ST697,
 374 ST873, and ST969. Of note, the globally disseminated ST258 clone, which is responsible for a
 375 large number of hospital deaths (39), was not identified in our dataset. However, we
 376 identified another globally disseminated clone, ST395, which has also been retrieved from
 377 clinical cases in Europe and Asia (40). Concerningly, this ST395 isolate, SCHI0016.S.137,
 378 carried both the ESBL genes *bla*_{SHV-11} and *bla*_{CTX-M-15} and the OXA-48-like carbapenemase,
 379 *bla*_{OXA-232}, the latter of which confers low-level meropenem resistance. Additionally, we
 380 observed one *K. pneumoniae* ST307, which is an emerging multi-drug resistant, globally
 381 disseminated clone postulated to have emerged in the mid-1990s(41). Although reports of
 382 this clone from Australian populations in uncommon it has been previously observed(41).

383
 384 This study had several recognized limitations. First, isolates were collected from a
 385 nosocomial setting; no community sources were sampled. It is well-established that
 386 differences in AMR patterns and their associated molecular mechanisms exist between
 387 hospital and community settings. Second, the absence of certain high-risk populations within
 388 our hospital (e.g. solid organ or hematopoietic stem cell transplantation) limits the

389 generalizability of our findings to other settings. Third, our PCR assays can only identify the
390 presence or change in copy number of the most common ESBL and *ampC* genes. Although
391 these loci make up the majority (>90%) of β -lactamase enzymes present in 3GC-R
392 Enterobacteriaceae, they do not capture all potential ESBLs, leaving less common ESBL and
393 *ampC* genes unidentified. In addition, PCR assays for *bla*_{TEM} or *bla*_{SHV} cannot discriminate
394 between ESBLs and non-ESBLs, with additional assays or concurrent WGS required to
395 confirm ESBL status. Our assays also cannot detect chromosomal changes leading to AMR
396 (e.g. porin mutations or efflux pump up-regulation), making these assays less useful for 3GC-
397 R bacteria that frequently encode these AMR determinants (e.g. *Pseudomonas aeruginosa*).
398 Fourth, our PCR was unable to distinguish chromosomal vs. low-copy plasmid-borne β -
399 lactamase genes, which has implications for AMR transmissibility between and among
400 bacterial populations. Finally, ~40% of samples were obtained from rectal swabs, which have
401 limitations for detection of multidrug-resistant organisms due to the high microbial burden
402 coupled with difficulties in sample collection. It is therefore likely that we did not capture all
403 3GC-R isolates during our study period, and thus may have missed potential transmission
404 events.

405

406

407 **Conclusion**

408

409 Taken together, our findings identified a predominance of CTX-M (and to a lesser extent,
410 CMY) β -lactamases among 3GC-R Enterobacteriaceae in the Sunshine Coast region. These
411 findings are consistent with global findings of Gram-negative bacterial AMR determinants,
412 particularly among *E. coli*. Our study demonstrates the likely absence of 3GC-R
413 Enterobacteriaceae transmission in our ICU setting, indicating effective infection control
414 processes. We show that rapid molecular assays, such as our multiplex PCR, can detect
415 common β -lactamase genes from bacterial culture within 40 minutes. These early molecular
416 results would permit more informed selection of antibiotic therapy up to 1-2 days prior to
417 3GC-R confirmation with traditional culture methodologies. Further research is required to
418 determine whether these molecular assays can be used directly on clinical specimens, and
419 whether the implementation of molecular assays and more advanced technologies (e.g.
420 WGS) is associated with improved patient outcomes in the hospital setting.

421

422 **Acknowledgements and funding**

423

424 This study was funded by the Wishlist Sunshine Coast Health Foundation (awarded to AGS,
425 KC, SS, and DSS). DSS and EPP were funded by Advance Queensland (grants AQR13016-
426 17RD2 and AQIRF0362018, respectively). We thank Dr Delaney Burnard (University of
427 Queensland Centre for Clinical Research) and the Sunshine Coast University Hospital
428 pathology laboratory for laboratory assistance, and Rhys T. White (University of Queensland)
429 for helpful feedback on this manuscript.

Figures

Figure 1: Singleplex and quadriplex PCR performance on third-generation cephalosporin-resistant Enterobacteriaceae. 1: *Enterobacter cloacae* SCHI0016.S.104 containing CMY. 2: *Escherichia coli* SCHI0016.S.205 containing TEM. 3A: *E. coli* SCHI0016.S.187 positive for CTX-M group 1. 3B: *E. coli* SCHI0016.S.60 positive for both CTX-M groups 1 and 9. 3C: *E. coli* SCHI0046.S.46. 3D: *E. coli* with only 16s rDNA amplification with no CTX-M or SHV detected. Note that both 16S rDNA and the TEM assays have late amplification in the no-template controls due to low levels of recombinant *E. coli* DNA present in the Sso Advanced *Taq* polymerase.

441

442

443 **Figure 2. Limits of Detection (LoD) and Quantitation (LoQ) for the extended spectrum β -**

444 **lactamase real-time PCR assays developed in this study. The bla_{CMY} and bla_{TEM} assays were**

445 **examined as singleplex PCRs, whereas the 16S rDNA, $bla_{CTX-M-1}$ group, $bla_{CTX-M-9}$ group, and**

446 **bla_{SHV} assays were examined in quadriplex format.**

447

448

449 **Figure 3. Whole-genome phylogeny of 79 third-generation cephalosporin-resistant**

450 *Escherichia coli* isolates and their β -lactamase gene complement. Sequence type (ST)131 is

451 indicated by the gray-shaded box; strains isolated from intensive care unit patients are

452 highlighted in green.

453

454

455 **Figure 4. Whole-genome phylogeny and β -lactamase enzyme presence in *Klebsiella***

456 ***pneumoniae*.** Green-shaded isolates were isolated from the intensive care unit.

457

458

459 **Transparency declarations**

460 Dr. Harris reports research grants from Shionogi, Sandoz, and MSD and speaker's fees from

461 Pfizer, outside the submitted work. No conflicts are declared for remaining authors

462
463

References

- 464 1. Gupta V, Ye G, Olesky M, Lawrence K, Murray J, Yu K. 2019. National
465 prevalence estimates for resistant Enterobacteriaceae and Acinetobacter
466 species in hospitalized patients in the United States. *Int J Infect Dis*
467 doi:10.1016/j.ijid.2019.06.017.
- 468 2. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. 2016.
469 Colonization and infection with extended spectrum beta-lactamase
470 producing Enterobacteriaceae in high-risk patients - Review of the
471 literature from a clinical perspective. *Crit Rev Microbiol* 42:1-16.
- 472 3. Anonymous. 2014. Antimicrobial resistance - global report on
473 surveillance 2014.
474 [https://apps.who.int/iris/bitstream/handle/10665/112642/978924156](https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=519244EE0EEF520027CE4098504150B4?sequence=1)
475 [4748_eng.pdf;jsessionid=519244EE0EEF520027CE4098504150B4?seque](https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=519244EE0EEF520027CE4098504150B4?sequence=1)
476 [nce=1](https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=519244EE0EEF520027CE4098504150B4?sequence=1). Accessed
- 477 4. Anonymous. 2018. Gram-negative Sepsis Outcome Program 2018 Report.
478 Australian Group on Antimicrobial Resistance
- 479 5. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a
480 clinical update. *Clin Microbiol Rev* 18:657-86.
- 481 6. Consortium BaB. 2015. Technology overview | BD MAX Enteric Bacterial
482 Panel for identifying pathogens in contagious gastroenteritis | Advice |
483 NICE, on National Institute for Health and Care Excellence.
484 <https://www.nice.org.uk/advice/mib32/chapter/Technology-overview>.
485 Accessed 14-2-2020.
- 486 7. MacVane SH, Nolte FS. 2016. Benefits of Adding a Rapid PCR-Based Blood
487 Culture Identification Panel to an Established Antimicrobial Stewardship
488 Program. *J Clin Microbiol* 54:2455-63.
- 489 8. Echavarria M, Marcone DN, Querci M, Seoane A, Ypas M, Videla C, O'Farrell
490 C, Vidaurreta S, Ekstrom J, Carballal G. 2018. Clinical impact of rapid
491 molecular detection of respiratory pathogens in patients with acute
492 respiratory infection. *J Clin Virol* 108:90-95.
- 493 9. Souverein D, Euser SM, van der Reijden WA, Herpers BL, Kluytmans J,
494 Rossen JWA, Den Boer JW. 2017. Clinical sensitivity and specificity of the
495 Check-Points Check-Direct ESBL Screen for BD MAX, a real-time PCR for
496 direct ESBL detection from rectal swabs. *J Antimicrob Chemother*
497 72:2512-2518.
- 498 10. Yang S, Lin S, Kelen GD, Quinn TC, Dick JD, Gaydos CA, Rothman RE. 2002.
499 Quantitative multiprobe PCR assay for simultaneous detection and
500 identification to species level of bacterial pathogens. *J Clin Microbiol*
501 40:3449-54.
- 502 11. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M,
503 Rozen SG. 2012. Primer3--new capabilities and interfaces. *Nucleic Acids*
504 *Res* 40:e115.
- 505 12. Bae IK, Kang HK, Jang IH, Lee W, Kim K, Kim JO, Jeong SH, Lee K. 2015.
506 Detection of Carbapenemases in Clinical Enterobacteriaceae Isolates
507 Using the VITEK AST-N202 Card. *Infect Chemother* 47:167-74.
- 508 13. Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH,
509 Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell

- J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL, Investigators MT, the Australasian Society for Infectious Disease Clinical Research N. 2018. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. *JAMA* 320:984-994.
14. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30:2114-20.
15. Price EP, Viberg LT, Kidd TJ, Bell SC, Currie BJ, Sarovich DS. 2018. Transcriptomic analysis of longitudinal *Burkholderia pseudomallei* infecting the cystic fibrosis lung. *Microb Genom* 4.
16. Wood DE, Lu J, Langmead B. 2019. Improved metagenomic analysis with Kraken 2. *Genome Biol* 20:257.
17. Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. 2017. metaSPAdes: a new versatile metagenomic assembler. *Genome Res* 27:824-834.
18. Antipov D, Hartwick N, Shen M, Raiko M, Lapidus A, Pevzner PA. 2016. plasmidSPAdes: assembling plasmids from whole genome sequencing data. *Bioinformatics* 32:3380-3387.
19. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. *J Mol Biol* 215:403-10.
20. Wu YW, Simmons BA, Singer SW. 2016. MaxBin 2.0: an automated binning algorithm to recover genomes from multiple metagenomic datasets. *Bioinformatics* 32:605-7.
21. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, Lago BA, Dave BM, Pereira S, Sharma AN, Doshi S, Courtot M, Lo R, Williams LE, Frye JG, Elsayegh T, Sardar D, Westman EL, Pawlowski AC, Johnson TA, Brinkman FS, Wright GD, McArthur AG. 2017. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. *Nucleic Acids Res* 45:D566-D573.
22. Sarovich DS, Price EP. 2014. SPANDx: A genomics pipeline for comparative analysis of large haploid whole genome re-sequencing datasets. *BMC Res Notes* 7:618.
23. Aziz A, Currie BJ, Mayo M, Sarovich DS, Price EP. 2020. Comparative genomics confirms a rare melioidosis human-to-human transmission event and reveals incorrect phylogenomic reconstruction due to polyclonality. *Microb Genom* doi:10.1099/mgen.0.000326.
24. Hayashi T, Makino K, Ohnishi M, Kurokawa K, Ishii K, Yokoyama K, Han CG, Ohtsubo E, Nakayama K, Murata T, Tanaka M, Tobe T, Iida T, Takami H, Honda T, Sasakawa C, Ogasawara N, Yasunaga T, Kuhara S, Shiba T, Hattori M, Shinagawa H. 2001. Complete genome sequence of enterohemorrhagic *Escherichia coli* O157:H7 and genomic comparison with a laboratory strain K-12. *DNA Res* 8:11-22.
25. Liu P, Li P, Jiang X, Bi D, Xie Y, Tai C, Deng Z, Rajakumar K, Ou HY. 2012. Complete genome sequence of *Klebsiella pneumoniae* subsp. *pneumoniae* HS11286, a multidrug-resistant strain isolated from human sputum. *J Bacteriol* 194:1841-2.

- 558 26. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zobel J,
559 Holt KE. 2014. SRST2: Rapid genomic surveillance for public health and
560 hospital microbiology labs. *Genome Med* 6:90.
- 561 27. Wilgenbusch JC, Swofford D. 2003. Inferring evolutionary trees with
562 PAUP*. *Curr Protoc Bioinformatics Chapter 6:Unit 6 4*.
- 563 28. Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates
564 and new developments. *Nucleic Acids Res* 47:W256-W259.
- 565 29. Harris PNA, Ben Zakour NL, Roberts LW, Wailan AM, Zowawi HM,
566 Tambyah PA, Lye DC, Jureen R, Lee TH, Yin M, Izharuddin E, Looke D,
567 Runnegar N, Rogers B, Bhally H, Crowe A, Schembri MA, Beatson SA,
568 Paterson DL, investigators MT. 2018. Whole genome analysis of
569 cephalosporin-resistant *Escherichia coli* from bloodstream infections in
570 Australia, New Zealand and Singapore: high prevalence of CMY-2
571 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27. *J*
572 *Antimicrob Chemother* 73:634-642.
- 573 30. Liakopoulos A, Mevius D, Ceccarelli D. 2016. A Review of SHV Extended-
574 Spectrum beta-Lactamases: Neglected Yet Ubiquitous. *Front Microbiol*
575 7:1374.
- 576 31. Orenica MC, Yoon JS, Ness JE, Stemmer WP, Stevens RC. 2001. Predicting
577 the emergence of antibiotic resistance by directed evolution and
578 structural analysis. *Nat Struct Biol* 8:238-42.
- 579 32. Jacoby GA. 2009. AmpC beta-lactamases. *Clin Microbiol Rev* 22:161-82,
580 Table of Contents.
- 581 33. Meini S, Tascini C, Cei M, Sozio E, Rossolini GM. 2019. AmpC beta-
582 lactamase-producing Enterobacterales: what a clinician should know.
583 *Infection* 47:363-375.
- 584 34. Cheng L, Nelson BC, Mehta M, Seval N, Park S, Giddins MJ, Shi Q, Whittier
585 S, Gomez-Simmonds A, Uhlemann AC. 2017. Piperacillin-Tazobactam
586 versus Other Antibacterial Agents for Treatment of Bloodstream
587 Infections Due to AmpC beta-Lactamase-Producing Enterobacteriaceae.
588 *Antimicrob Agents Chemother* 61.
- 589 35. Grayson ML, Stewardson AJ, Russo PL, Ryan KE, Olsen KL, Havers SM,
590 Greig S, Cruickshank M, Hand Hygiene A, the National Hand Hygiene I.
591 2018. Effects of the Australian National Hand Hygiene Initiative after 8
592 years on infection control practices, health-care worker education, and
593 clinical outcomes: a longitudinal study. *Lancet Infect Dis* 18:1269-1277.
- 594 36. Giedraitiene A, Vitkauskienė A, Pavilionis A, Patamsyte V, Genel N, Decre D,
595 Arlet G. 2017. Prevalence of O25b-ST131 clone among *Escherichia coli*
596 strains producing CTX-M-15, CTX-M-14 and CTX-M-92 beta-lactamases.
597 *Infect Dis (Lond)* 49:106-112.
- 598 37. Nicolas-Chanoine MH, Bertrand X, Madec JY. 2014. *Escherichia coli* ST131,
599 an intriguing clonal group. *Clin Microbiol Rev* 27:543-74.
- 600 38. Tchesnokova V, Radey M, Chattopadhyay S, Larson L, Weaver JL, Kisiela D,
601 Sokurenko EV. 2019. Pandemic fluoroquinolone resistant *Escherichia coli*
602 clone ST1193 emerged via simultaneous homologous recombinations in
603 11 gene loci. *Proc Natl Acad Sci U S A* 116:14740-14748.
- 604 39. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K,
605 Goater R, Giani T, Errico G, Aspbury M, Sjunnebo S, Eu SWG, Group ES, Feil
606 EJ, Rossolini GM, Aanensen DM, Grundmann H. 2019. Epidemic of

607 carbapenem-resistant *Klebsiella pneumoniae* in Europe is driven by
608 nosocomial spread. *Nat Microbiol* doi:10.1038/s41564-019-0492-8.
609 40. Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. 2016. Global
610 Dissemination of Carbapenemase-Producing *Klebsiella pneumoniae*:
611 Epidemiology, Genetic Context, Treatment Options, and Detection
612 Methods. *Front Microbiol* 7:895.
613 41. Wyres KL, Hawkey J, Hetland MAK, Fostervold A, Wick RR, Judd LM,
614 Hamidian M, Howden BP, Lohr IH, Holt KE. 2019. Emergence and rapid
615 global dissemination of CTX-M-15-associated *Klebsiella pneumoniae*
616 strain ST307. *J Antimicrob Chemother* 74:577-581.
617

618

619

Tables

Table 1: Summary of antimicrobial resistance mechanisms among 288 clinical Enterobacteriaceae isolates retrieved from 264 patients admitted to a Southeast Queensland hospital over a 14-month period.

Organism	<i>E. coli</i> (n=231)	<i>K. pneumoniae</i> (n=49)	<i>K. aerogenes</i> (n=1)	<i>K. oxytoca</i> (n=3)	<i>E. cloacae</i> (n=4)
Phenotypic antimicrobial resistance^a					
Ceftriaxone	223 (96.5%)	46 (93.9%)	1 (100%)	3 (100%)	4 (100%)
Ceftazidime	215 (93.1%)	47 (95.9%)	1 (100%)	2 (66.7%)	4 (100%)
Cefepime	201 (87.0%)	43 (87.8%)	1 (100%)	2 (66.7%)	3 (75.0%)
Cefoxitin	64 (27.7%)	12 (24.5%)	1 (100%)	0 (0%)	4 (100%)
Piperacillin-tazobactam	65 (28.1%)	31 (63.3%)	1 (100%)	3 (100%)	4 (100%)
Ticarcillin-clavulanate	186 (80.5%)	46 (93.9%)	0 (0%)	3 (100%)	3 (75.0%)
Meropenem	3 (1.3%)	2 (4.1%)	0 (0%)	0 (0%)	3 (75.0%)
ESBL phenotypic test^b					
Positive	204 (88.3%)	46 (93.9%)	0 (0%)	2 (66.7%)	4 (100%)
Negative	27 (11.7%)	3 (6.1%)	1 (100%)	1 (33.3%)	0 (0%)
ESBL and <i>ampC</i> gene prevalence					
<i>bla</i> _{CTX-M-1}	104 (45.0%)	36 (73.5%)	0 (0%)	2 (66.7%)	2 (50.0%)
<i>bla</i> _{CTX-M-9}	89 (38.5%)	4 (8.2%)	0 (0%)	0 (0%)	0 (0%)
<i>bla</i> _{SHV}	9 (3.9%)	38 (77.6%)	0 (0%)	0 (0%)	1 (25.0%)
<i>bla</i> _{TEM}	93 (40.3%)	33 (67.3%)	0 (0%)	2 (66.7%)	2 (50.0%)
<i>bla</i> _{CMY}	30 (13.0%)	3 (6.1%)	0 (0%)	0 (0%)	1 (25.0%)
PCR-negative ^c	7 (3.0%)	1 (4%)	1 (100%)	1 (33.3%)	1 (25.0%)

^aAntimicrobial susceptibility testing performed by automated method (VITEK 2®) and EUCAST breakpoints applied

^bESBL phenotypic testing performed by disc diffusion method

^cDNA integrity was confirmed by 16S rDNA PCR (10), which forms part of the quadriplex assay. Three PCR negative *E. coli* strains encoded *bla*_{DHA-1}, one *E. cloacae* encoded *bla*_{ACT-17}, one *K. oxytoca* encoded a *bla*_{OXY-2-1}, a second *K. oxytoca* (included as a mixture with *K. pneumoniae*) encoded *bla*_{OXY-2-4}, and 5/11 isolates had no β -lactamases identified despite whole-genome sequencing.